DRTS
Alpha Tau Medical Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$15.24
−1.61%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$15.43
From 52W high−1.61%
Volume589689.00
Market cap$1.41B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$15.43
From 52W high
−1.61%
Volume
589689.00
Market cap
$1.41B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−26.9x
P/E (TTM)
—
RSI (14)
59.7
MomentumView details →
1D Return
−1.61%
YTD Return
+205.96%
SummaryUpdated Jun 1, 2026
Alpha Tau Medical Ltd. (NASDAQ:DRTS) is a clinical-stage oncology therapeutics company founded in 2015 and headquartered in Jerusalem, Israel. The company went public in March 2021 and focuses on developing innovative radiation therapy technology for treating solid tumors. Alpha Tau's core innovation centers around a proprietary technology called Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), which represents a novel approach to cancer treatment using radioactive alpha particles delivered directly to tumor sites.
Similar companies
Latest newsMore news →
Alpha Tau Medical completed patient enrollment in its multicenter IMPACT pilot study of Alpha DaRT for unresectable pancreatic cancer, expanding enrollment from 12 to 48 patients.20d agoAlpha Tau Medical reported positive clinical data for Alpha DaRT in combination with pembrolizumab in head and neck cancer at the AHNS conference on July 21, 2026.61d agoAlpha Tau successfully treated the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma in its ADMIRE study at Banner MD Anderson Cancer Center.67d ago